Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 9/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27992607 | 0.88 | HCAR3 (0.54) | HCAR3DEGS1HCAR2NNMTHDAC1 | |
| SCHEMBL16754096 | 0.80 | GRIN2B (0.45) | HCAR3DEGS1HCAR2HDAC1 | |
| SCHEMBL7093993 | 0.80 | PTK2 (0.62) | PTK2HCAR3CYP1A2GAAKMT2A | |
| SCHEMBL20159392 | 0.79 | PTK2 (0.47) | PTK2HCAR3CYP1A2GAADEGS1 | |
| SCHEMBL13321611 | 0.78 | MEN1 (0.50) | HCAR3CYP1A2GAADEGS1KMT2A | |
| SCHEMBL82675 | 0.78 | HCAR3 (0.68) | PTK2HCAR3CYP1A2GAAHCAR2 | |
| SCHEMBL25190504 | 0.77 | PTK2 (0.59) | PTK2HCAR3CYP1A2GAAKMT2A | |
| SCHEMBL3465475 | 0.77 | NNMT (0.69) | PTK2HCAR3CYP1A2GAANNMT | |
| SCHEMBL1203341 | 0.76 | PTK2 (0.54) | PTK2HCAR3CYP1A2GAADEGS1 | |
| SCHEMBL1854705 | 0.76 | MAPK1 (0.59) | PTK2HCAR3CYP1A2GAADEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
| WO-2014059333-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044152-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | PTK2 1528/4885HCAR3 550/4885CYP1A2 4570/4885 |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | PTK2 1528/4885HCAR3 550/4885CYP1A2 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.